Skip to main content
SpringerLink
Log in

Die Therapie der allergischen Rhinitis in der Routineversorgung: evidenzbasierte Nutzenbewertung der kombinierten Anwendung mehrerer Wirkstoffe

  • Übersicht
  • Die Therapie der allergischen Rhinitis in der Routineversorgung
  • Published:
Allergo Journal Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB et al; Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010;126:466-76

  2. Marple BF, Fornadley JA, Patel AA, Fineman SM, Fromer L, Krouse JH et al; American Academy of Otolaryngic Allergy Working Group on Allergic Rhinitis. Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction. Otolaryngol Head Neck Surg 2007;136(6 Suppl):S107-24

  3. Khan MA, Abou-Halawa AS, Al-Robaee AA, Alzolibani AA, Al-Shobaili HA. Daily versus self-adjusted dosing of topical mometasone furoate nasal spray in patients with allergic rhinitis: randomised, controlled trial. J Laryngol Otol 2010;124:397-401

  4. Bousquet J, Arnavielhe S, Bedbrook A, Bewick M, Laune D, Mathieu-Dupas E et al; MASK study group. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. Clin Transl Allergy 2018;8:45

  5. Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol 2017;140:950-8

  6. Bousquet J, Pfaar O, Togias A, Schünemann HJ, Ansotegui I, Papadopoulos NG et al; ARIA-Arbeitsgruppe. Positionspapier. ARIA-Versorgungspfade für die Allergenimmuntherapie 2019. Allergologie 2019;42:404-25

  7. Blaiss MS. Important aspects in management of allergic rhinitis: compliance, cost, and quality of life. Allergy Asthma Proc 2003;24:231-8

  8. Meltzer EO. An overview of current pharmacotherapy in perennial rhinitis. J Allergy Clin Immunol 1995;95(5 Pt 2):1097-110

  9. Price D, Scadding G, Ryan D, Bachert C, Canonica GW, Mullol J et al. The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey. Clin Transl Allergy 2015;5:39

  10. Hellings PW, Fokkens WJ, Akdis C, Bachert C, Cingi C, Dietz de Loos D et al. Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today? Allergy 2013;68:1-7

  11. Bousquet J, Schunemann HJ, Fonseca J, Samolinski B, Bachert C, Canonica GW et al. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy 2015; 70:1372-92

  12. Bousquet J, Schünemann HJ, Hellings PW, Arnavielhe S, Bachert C, Bedbrook A et al; MASK study group*. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol 2016;138:367-74.e2

  13. Interdisziplinäre Arbeitsgruppe "Allergische Rhinitis" der Sektion HNO. Allergische Rhinokonjunktivitis - Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAI). Allergo J 2003;12:182-94

  14. Ratner PH, Ehrlich PM, Fineman SM, Meltzer EO, Skoner DP. Use of intranasal cromolyn sodium for allergic rhinitis. Mayo Clin Proc 2002;77:350-4

  15. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983;220:568-75

  16. Rodrigo GJ, Yañez A. The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials. Ann Allergy Asthma Immunol 2006;96:779-86

  17. Lehtimäki L, Petäys T, Haahtela T. Montelukast is not effective in controlling allergic symptoms outside the airways: a randomised double-blind placebo-controlled crossover study. Int Arch Allergy Immunol 2009;149:150-3

  18. Stokes JR, Romero FA Jr, Allan RJ, Phillips PG, Hackman F, Misfeldt J et al. The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms. J Allergy Clin Immunol 2012;129:409-12,412.e1-2

  19. Kay GG, Quig ME. Impact of sedating antihistamines on safety and productivity. Allergy Asthma Proc 2001; 22:281-3

  20. Newson-Smith G, Powell M, Baehre M, Garnham SP, MacMahon MT. A placebo controlled study comparing the efficacy of intranasal azelastine and beclomethasone in the treatment of seasonal allergic rhinitis. Eur Arch Otorhinolaryngol 1997;254:236-41

  21. Mullol J, Bousquet J, Bachert C, Canonica WG, Gimenez-Arnau A, Kowalski ML et al. Rupatadine in allergic rhinitis and chronic urticaria. Allergy 2008;63 Suppl 87:5-28

  22. Thorn C, Pfaar O, Hörmann K, Klimek L. Rupatadin - Pharmakologie, klinische Wirksamkeit und therapeutische Sicherheit eines neuen Antihistamins mit zusätzlicher, PAF-antagonisierender Wirkung. Allergologie 2010;33:429-40

  23. Perez I, Villa M, De La Cruz G. Rupatadine in allergic rhinitis: Pooled analysis of efficacy data. Allergy 2002;57:245

  24. Yamamoto H, Yamada T, Kubo S, Osawa Y, Kimura Y, Oh M et al. Efficacy of oral olopatadine hydrochloride for the treatment of seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled study. Allergy Asthma Proc 2010;31:296-303

  25. Sádaba Díaz de Rada B, Azanza Perea JR, Gomez-Guiu Hormigos A. Bilastine for the relief of allergy symptoms. Drugs Today (Barc) 2011;47:251-62

  26. Kuna P, Bachert C, Nowacki Z, van Cauwenberge P, Agache I, Fouquert L et al.; Bilastine International Working Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy 2009;39:1338-47

  27. Zuberbier T, Oanta A, Bogacka E, Medina I, Wesel F, Uhl P et al.; Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010;65:516-28

  28. Bachert C, Kuna P, Sanquer F, Ivan P, Dimitrov V, Gorina MM et al.; Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009;64:158-65

  29. Yañez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002;89:479-84

  30. 30. Kaliner MA, Berger WE, Ratner PH, Siegel CJ. The efficacy of intranasal antihistamines in the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 2011;106(2 Suppl):S6-S11

  31. Okano M. Mechanisms and clinical implications of glucocorticosteroids in the treatment of allergic rhinitis. Clin Exp Immunol 2009;158:164-73

  32. Klimek L, Högger P, Pfaar O. Wirkmechanismen nasaler Glukokortikosteroide in der Therapie der allergischen Rhinitis. Teil 1: Pathophysiologie, molekulare Grundlagen. Mechanism of action of nasal glucocorticosteroids in the treatment of allergic rhinitis. Part 1: Pathophysiology, molecular basis. HNO 2012;60:611-7

  33. Skoner DP, Rachelefsky GS, Meltzer EO, Chervinsky P, Morris RM, Seltzer JM et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 2000;105:E23

  34. Bernstein JA. Evaluating the effectiveness of medications in the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 2010;105:189; author reply 189

  35. Benninger M, Farrar JR, Blaiss M, Chipps B, Ferguson B, Krouse J et al. Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class. Ann Allergy Asthma Immunol 2010;104:13-29

  36. Bousquet J, Pfaar O, Togias A, Schünemann HJ, Ansotegui I, Papadopoulos NG et al.; ARIA Working Group 2019 ARIA Care pathways for allergen immunotherapy. Allergy 2019;74:2087-102

  37. Bédard A, Basagaña X, Anto JM, Garcia-Aymerich J, Devillier P, Arnavielhe S et al.; MASK study group. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. J Allergy Clin immunol 2019;144:135-43.e6

  38. Bousquet J, Devillier P, Arnavielhe S, Bedbrook A, Alexis-Alexandre G, van Eerd M et al. Treatment of allergic rhinitis using mobile technology with real-world data: The MASK observational pilot study. Allergy 2018;73:1763-74

  39. Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC. A survey of the burden of allergic rhinitis in Europe. Allergy 2007;62 Suppl 85:17-25

  40. Dalal AA, Stanford R, Henry H, Borah B. Economic burden of rhinitis in managed care: a retrospective claims data analysis. Ann Allergy Asthma Immunol 2008;101:23-9

  41. Day JH, Briscoe MP, Ratz JD, Danzig M, Yao R. Efficacy of loratadine-montelukast on nasal congestion in patients with seasonal allergic rhinitis in an environmental exposure unit. Ann Allergy Asthma Immunol 2009;102:328-38

  42. Meltzer EO, Malmstrom K, Lu S, Prenner BM, Wei LX, Weinstein SF et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 2000;105:917-22

  43. Prenner P, Anolik R, Danzig M, Yao R. Efficacy and safety of fixed-dose loratadine/montelukast in seasonal allergic rhinitis: effects on nasal congestion. Allergy Asthma Proc 2009;30:263-9

  44. Cingi C, Gunhan K, Gage-White L, Unlu H. Efficacy of leukotriene antagonists as concomitant therapy in allergic rhinitis. Laryngoscope 2010;120:1718-23

  45. MSD. SINGULAIR® - Fachinformation (Zusammenfassung der Merkmale der Arzneimittel). MSD Sharp & Dohme GmbH 2019. [URL: https://www.msd.de/fileadmin/files/fachinformationen/singulair.pdf] und [Rote Liste Service GmbH, URL: https://www.patienteninfo-service.de/a-z-liste/s/]

  46. Seresirikachorn K, Chitsuthipakorn W, Kanjanawasee D, Khattiyawittayakun L, Snidvongs K. Effects of H1 antihistamine addition to intranasal corticosteroid for allergic rhinitis: a systematic review and meta-analysis. Int Forum Allergy Rhinol 2018;8:1083-92

  47. Bousquet J, Meltzer EO, Couroux P, Koltun A, Kopietz F, Munzel U et al. Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber. J Allergy Clin Immunol Pract 2018;6:1726-32.e6

  48. Feng S, Fan Y, Liang Z, Ma R, Cao W. Concomitant corticosteroid nasal spray plus antihistamine (oral or local spray) for the symptomatic management of allergic rhinitis. Eur Arch Otorhinolaryngol 2016;273:3477-86

  49. Ratner PH, Hampel F, Van Bavel J, Amar NJ, Daftary P, Wheeler W et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2008;100:74-81

  50. Hampel FC, Ratner PH, Van Bavel J, Amar NJ, Daftary P, Wheeler W et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol 2010;105: 168-73

  51. Leung DY M, Szefler J (Associate Editors of the JACI). The Editors' Choice. J Allergy Clin Immunol 2012;129:1216-7. DOI: https://doi.org/10.1016/j.jaci.2012.03.019

  52. Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D, Carr W. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc 2012;33:324-32

  53. Portmann D, Le Gal M, Jessent V, Verrière JL. [Acceptability of local treatment of allergic rhinitis with a combination of a corticoid (beclomethasone) and an antihistaminic (azelastine)]. Rev Laryngol Otol Rhinol (Bord) 2000;121:273-9

  54. Anolik R. Mometasone furoate nasal spray with loratadine study group. Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2008;100:264-71

  55. Di Lorenzo G, Pacor ML, Pellitteri ME, Morici G, Di Gregoli A, Lo Bianco C et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy 2004;34:259-67

  56. van Galen KA, Nellen JF, Nieuwkerk PT. The Effect on Treatment Adherence of Administering Drugs as Fixed-Dose Combinations versus as Separate Pills: Systematic Review and Meta-Analysis. AIDS Red Treat 2014;2014:967073

  57. D'Addio AD, Ruiz NM, Mayer MJ, Berger W, Meltzer EO. Quantification of the Distribution of MP29-02 (Dymista-Azelastine HCl/Fluticasone Propionate Nasal Spray) in an Anatomical Model of the Human Nasal Cavity. Poster Session. AAAAI Annual Meeting 2015, Houston, Texas. [URL: https://www.eposters.net/pdfs/quantification-of-the-distribution-of-mp29-02-dymista-azelastine-hclfluticasone-propionate-nasal.pdf]

  58. Bernstein JA. Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. Curr Med Res Opin 2007;23:2441-52

  59. Shaw RJ. Pharmacology of fluticasone propionate. Respir Med 1994;88 Suppl A:5-8

  60. Pfaar O, Bachert C, Bufe A, Buhl R, Ebner C, Eng P et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Allergo J Int 2014;23:282-319

  61. Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012;129:1282-9.e10

  62. Harrow B, Sedaghat AR, Caldwell-Tarr A, Dufour R. A Comparison of Health Care Resource Utilization and Costs for Patients with Allergic Rhinitis on Single-Product or Free-Combination Therapy of Intranasal Steroids and Intranasal Antihistamines. J Manag Care Spec Pharm 2016;22:1426-36

  63. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-9

  64. Patel P, Salapatek AM, Tantry SK. Effect of olopatadine-mometasone combination nasal spray on seasonal allergic rhinitis symptoms in an environmental exposure chamber study. Ann Allergy Asthma Immunol 2019;122:160-6.e1

  65. Patel P, Salapatek AM, Talluri RS, Tantry SK. Pharmacokinetics of intranasal olopatadine in the fixed-dose combination GSP301 versus two monotherapy intranasal olopatadine formulations. Allergy Asthma Proc 2018;39:224-31

  66. Patel P, Salapatek AM, Talluri RS, Tantry SK. Pharmacokinetics of intranasal mometasone in the fixed-dose combination GSP301 versus two monotherapy intranasal mometasone formulations. Allergy Asthma Proc 2018;39:232-9

  67. Ledford DK. Omalizumab: overview of pharmacology and efficacy in asthma. Expert Opin Biol Ther 2009;9:933-43

  68. Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respir Med 2008;102:1371-8

  69. Kamin W, Kopp MV, Erdnuess F, Schauer U, Zielen S, Wahn U. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol 2010;21(1 Pt 2):e160-5

  70. Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C et al.; DUAL study group. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 2009;39:271-9

  71. Stock P, Rolinck-Werninghaus C, Wahn U, Hamelmann E. The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis. BioDrugs 2007;21:403-10

  72. Berger W, Bousquet J, Fox AT, Just J, Muraro A, Nieto A et al. MP-AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children. Allergy 2016;71:1219-22

  73. Haahr PA, Jacobsen C, Christensen ME. MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Denmark. Int Forum Allergy Rhinol 2019;9:388-95

  74. Kortekaas Krohn I, Callebaut I, Alpizar YA, Steelant B, Van Gerven L, Skov PS et al. MP29-02 reduces nasal hyperreactivity and nasal mediators in patients with house dust mite-allergic rhinitis. Allergy 2018;73:1084-93

Download references

Author information

Authors and Affiliations

  1. Zentrum für Rhinologie & Allergologie, An den Quellen 10, 65183, Wiesbaden, Germany

    Ludger Klimek

  2. Zentrum für Rhinologie und Allergologie, Wiesbaden, Germany

    Ingrid Casper

  3. Allergie-Centrum-Charite (Charite Campus Mitte), Luisenstr. 2-5, 10117, Berlin, Germany

    Karl-Christian Bergmann

  4. Klinik und Poliklinik für Dermatologie und Allergologie, Biedersteiner Str. 29, 80802, München, Germany

    Tilo Biedermann

  5. MACVIA-France, Montpellier, Frankreich

    Jean Bousquet

  6. Department of Otorhinolaryngology, University of Leuven, Löwen, Belgien

    Peter Hellings

  7. Gemeinschaftspraxis für Dermatologie, Krämpferstr. 6, 99096, Erfurt, Germany

    Kirsten Jung

  8. Klinik für Dermatologie und Allergologie, Uniklinik RWTH Aachen, Aachen, Germany

    Hans Merk

  9. Abteilung für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie, Charité –Universitätsmedizin Berlin, Berlin, Germany

    Heidi Olze

  10. CRI - Clinical Research International Ltd., Genter Straße 7, 50672, Köln, Germany

    Ralph Mösges

  11. HNO-Praxis Frankfurt am Main, Frankfurt, Germany

    Wolfgang Schlenter

  12. Klinik und Poliklinik für Hals-Nasen-Ohrenheilkunde, Klinikum der Universität München, Marchioninistraße 15, 81377, München, Germany

    Moritz Gröger

  13. Haut- und Laserzentrum an der Oper, Perusastraße 5, 80333, München, Germany

    Johannes Ring

  14. Klinikum rechts der Isar, Technische Universität München, München, Germany

    Adam Chaker

  15. Sektion für Rhinologie und Allergologie, Baldingerstraße, 35043, Marburg, Germany

    Oliver Pfaar

  16. Dermatologische Gemeinschaftspraxis, Warendorfer Str. 183, 48145, Münster, Germany

    Wolfgang Wehrmann

  17. Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany

    Torsten Zuberbier

  18. Klinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsklinikum Tübingen, Langenbeckstr. 1, 55131, Tübingen, Germany

    Sven Becker

Authors
  1. Ludger Klimek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ingrid Casper
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karl-Christian Bergmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tilo Biedermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jean Bousquet
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Peter Hellings
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kirsten Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hans Merk
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Heidi Olze
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ralph Mösges
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Wolfgang Schlenter
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Moritz Gröger
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Johannes Ring
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Adam Chaker
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Oliver Pfaar
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Wolfgang Wehrmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Torsten Zuberbier
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Sven Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sven Becker.

Ethics declarations

S. Becker hat Zuschüsse, Honorare und nicht finanzielle Unterstützung von Ambu, ALK-Abelló, Allergopharma, Bencard Allergie GmbH, Bristol-Myers Squibb, HAL Allergie und Sanofi Genzyme erhalten, außerhalb der vorliegenden Arbeit.

T. Biedermann hat Zuschüsse und/oder Honorare von Alk-Abelló, Astellas, Bencard, Biogen, Janssen, Leo, Meda, MSD, Novartis, Phadia und Thermo Fisher, außerhalb der vorliegenden Arbeit erhalten.

J. Bousquet hat außerhalb der vorliegenden Arbeit Honorare erhalten von und war beratend tätig (Beiratsmitglied, Vorträge) für: Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva, Uriach und Kyomed.

L. Klimek hat Zuschüsse und/oder Honorare von Allergopharma, Meda/Mylan, HAL Allergie, ALK-Abelló, Leti Pharma, Allergy Therapeutics, Stallergenes, Quintiles, Sanofi, AstraZeneca, GSK, ASIT Biotech und Lofarma erhalten, außerhalb der vorliegenden Arbeit. Außerdem ist L. Klimek Präsident des AeDA und Mitglied in folgenden Gesellschaften: DGHNO, DGAKI, GPA und EAACI.

R. Mösges hat Honorare und/oder Zuschüsse und/oder nicht finanzielle Unterstützung von ALK-Abelló, ASIT Biotech, Allergopharma, Allergy Therapeutics, Bencard, Leti Pharma, Lofarma, Roxall, Stallergenes, Optima, Friulchem, Hexal, Servier, Klosterfrau, Atmos, Bayer, Bionorica, FAES, GSK, MSD, Johnson & Johnson, Meda, Novartis, Otonomy, Stada, UCB, Ferrero, BitopAG, Hulka, Nuvo und Ursapharm erhalten, außerhalb der vorliegenden Arbeit.

H. Olze ist Beiratsmitglied bei Meda Pharma.

O. Pfaar hat Zuschüsse und/oder Honorare von ALK-Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding/HAL Allergie, Bencard Allergie/Allergy Therapeutics, Lofarma, Biomay, Circassia, ASIT Biotech Tools , Laboratorios Leti/Leti Pharma, Meda Pharma/Mylan, Anergis, Mobile Chamber Experts (a GA2LEN Partner), Indoor Biotechnologies, GSK, Astellas Pharma Global, Euforea, Roxall, Novartis und Sanofi Aventis erhalten, außerhalb der vorliegenden Arbeit.

J. Ring hat Honorare von Mylan, Allergika, Galderma, Sanofi-Genzyme, ThermoFisher und Leo Pharma erhalten, außerhalb der vorliegenden Arbeit.

T. Zuberbier hat Honorare (zum Beispiel für Vorträge, Beratungen, Gutachten) von Bayer Health Care, FAES, Novartis, Henkel, Novartis, Henkel, AstraZeneca, Abbvie, ALK, Almirall, Astellas, Bayer Health Care, Bencard, Berlin Chemie, FAES, HAL, Leti, Meda, Menarini, Merck MSD, Novartis, Pfizer, Sanofi, Stallergenes, Takeda, Teva, UCB, Henkel, Kryolan und L'Oréal erhalten, außerhalb der vorliegenden Arbeit.

KC Bergmann, I. Casper, A. Chaker, M. Gröger, P. Hellings, K. Jung, H. Merk, W. Schlenter, W. Wehrmann erklären, dass keine Interessenkonflikte bestehen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Klimek, L., Casper, I., Bergmann, KC. et al. Die Therapie der allergischen Rhinitis in der Routineversorgung: evidenzbasierte Nutzenbewertung der kombinierten Anwendung mehrerer Wirkstoffe. Allergo J 29, 14–24 (2020). https://doi.org/10.1007/s15007-020-2551-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15007-020-2551-0

Schlüsselwörter

Search

Navigation